Results about: p38 MAPK
The Signalling and Cell Cycle Laboratory focuses on studying the basic mechanisms of cell regulation, especially regarding how external signals are interpreted by cells to modulate cell proliferation, differentiation and survival. Our research centers on two main subjects:
p38α is a protein involved in chronic inflammatory diseases and cancer, among other pathological conditions.
Published in the journal eLife, the study provides a deeper understanding of the structure of this protein, thereby paving the way for the development of more effective inhibitors.
These findings are the result of combining fundamental biological data using computational techniques.
The European Research Council awards 45 scientists with grants to commercialize their research results
The grant, worth up to €150,000, cover costs of activities to verify the innovation potential of Nebreda’s ERC Advanced Grant-funded project
Nebreda will study new breast cancer therapies
The project, led by the scientist Raquel Batlle, receives a grant of 60,000 €.
The study will determine the potential of p38 protein as a therapeutic target or as a diagnostic indicator in colorectal cancer.
The team headed by Angel Rodríguez Nebreda, ICREA researcher at IRB, identifies for the first time in mice that the p38 MAPK protein is required for the survival and proliferation of colon cancer cells.
In the same study the scientists demonstrate that a p38 inhibitor that has been used in clinical trials for inflammatory diseases shrinks the tumours in mice.
The study, published today in Cancer Cell, has received funding from the BBVA Foundation, the European project InflaCare, the Spanish Government, and the European Research Council (ERC).